Histogen Plans New HSC Trial For Males

Today, Histogen CEO Richard Pascoe presented at the BIO Investor Forum in San Francisco, CA.

During his BIO presentation, Richard Pascoe discussed Histogen’s current therapeutic programs including dermal fillers, cartilage repair, and of course, hair growth. Pascoe shared that the company is planning to conduct a dose-ranging study for their lead product, HSC, in the first quarter of 2020. By nature, the study will seek to determine the optimal number of injections needed to create the greatest efficacy of hair growth. Only males subjects will be involved in this trial as Histogen does not wish to mix data between genders. An HSC trial for females was completed earlier this year. Men with a baldness pattern up to a Norwood 4A are eligible to participate in the upcoming trial which is a pretty significant degree of hair loss. The slide below displays the full trial protocol.

Pascoe stated that data will be expected from this trial in Q3 2020 and, if positive, would potentially lead Histogen to a clinical partner for the product. This seems important because if the HSC product got into the hands of a larger company, Allergan for example, it would likely get through the clinical trial process much faster than it has with Histogen alone. Many readers, including myself, may be surprised that this trial is labeled as a phase 1b which is early in the process. It seems that refining the composition of the HSC product has bound Histogen to showing safety once again in a phase 1b trial before moving into a late stage trial.

I would say the biggest positive from this presentation is Histogen’s plans to partner out HSC which could effectively end the long road of development that the product has been on.



Like this: Like Loading...